Experimental drug DCR-STAT3 tested in patients with stubborn cancers
NCT ID NCT06098651
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This early-stage trial tested an experimental drug called DCR-STAT3 in 26 adults with solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. Researchers gave increasing doses to find the best and safest amount.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Next Oncology
Dallas, Texas, 75039, United States
-
Next Oncology
San Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DCR-STAT3 (an experimental drug given intravenously)
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 26 participants, so safety and dosing are still being figured out. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.